CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Enstilar® foam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03506477
NCT03506477Phase 4Completed
CompareCT.gov

A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

Icahn School of Medicine at Mount Sinai·interventional·Posted Apr 24, 2018·Updated Jan 20, 2021

In Brief

A Phase 4 clinical trial evaluating Enstilar® foam and Vehicle foam for Plaque Psoriasis and Psoriasis. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in skin of color (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques in skin of color (and its change with Enstilar ® treatment) as well as the effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis, Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedApr 24, 2018
Enrollment StartMay 21, 2018
Primary CompletionSep 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.2 years ago

Interventions

Enstilar® foamdrug

for 4 weeks

Vehicle foamdrug

for 4 weeks